Archived Content


2nd Annual  

Antibody-Drug Conjugates May 3 - 4

Antibody-drug conjugates (ADCs) in late-stage clinical development have shown encouraging therapeutic effects against both solid tumors and hematological malignancies. Significant progress has been made through optimization of parameters including specificity, potency, linker technology, conjugate site design, and the stoichiometry and placement of drugs.  These sessions will showcase the design and discovery of next generation ADC’s, leveraging current knowledge from successful clinical candidates.

Day 1 | Day 2 | Download Brochure 


12:00 pm Registration



1:30 Chairperson’s Opening Remarks

Pamela-TrailPamela A. Trail, Ph.D., Vice President, Oncology, Regeneron Pharmaceuticals, Inc.

» 1:40 Featured Speaker 

Lessons Learned from the Clinic – T-DM1 and Beyond

John-LambertJohn Lambert, Ph.D., CSO, ImmunoGen, Inc. (biography)

Since 1999, a number of antibody-maytansinoid conjugates (AMCs) have entered clinical testing, with the most advanced of these, T-DM1 and SAR3419, attracting attention for their efficacy and tolerability profile. Lessons learned from earlier AMCs helped inform the design of these compounds, and this body of knowledge that can be applied to AMC design continues to expand and will be discussed.

» 2:10 Featured Speaker 

The Development of ADCs at Seattle Genetics

Jonathan-DrachmanJonathan Drachman, M.D., Senior Vice President, Research and Translational Medicine, Seattle Genetics (biography)

Antibody-drug conjugates (ADCs) represent an important class of new cancer therapeutics under development. The deceptively simple concept of targeted drug delivery has been an elusive goal for decades but has been realized with the approval of brentuximab vedotin (ADCETRIS).The current approach to designing empowered antibodies and testing them both pre-clinically and clinically will be discussed.

2:40 SAR3419, a DM4-Loaded Antibody-Drug Conjuguate: Phase I Experience in B-Cell Lymphoma

Anne Bousseau, M.D., Head, Early Development Projects, Global Oncology, Sanofi-Aventis (biography)

SAR3419 (huB4-DM4)is an antibody–drug conjugate composed of a humanized IgG1 monoclonal antibody, huB4 targeting the CD19 antigen, conjugated through a disulfide linker to a potent tubulin inhibitor, the maytansinoid derivative DM4.  This presentation will focus on the translation from pre-clinical to human. Pre-clinical activity as well as preliminary phase I data will be presented, including evidence for the mechanism of action in both tumor-bearing mice and patients.

3:10 Refreshment Break in the Exhibit Hall with Poster Viewing


4:00 Problem Solving Breakout Discussions

Concurrent problem solving breakout discussions, open to all attendees, speakers, sponsors, and exhibitors, provide a forum for discussing key issues and meeting potential collaborators. Plan to take part and explore these topics in-depth. Please pick a topic of your choice, find your table and join in.

Engineering Antibody-Drug Conjugates

Moderated by Pamela A. Trail, Ph.D., Vice President, Oncology, Regeneron Pharmaceuticals, Inc.

Translational Considerations from Pre-Clinical to Human Trials

Moderated by Anne Bousseau, M.D., Head, Early Development Projects, Global Oncology, Sanofi-Aventis

The Challenge of Bringing ADCs to the Clinic

Moderated by John Lambert, Ph.D., CSO, ImmunoGen, Inc.

Conjugation and Linker Chemistry for ADCs

Moderated by Edmund Graziani, Ph.D., Associate Research Fellow, Worldwide Medicinal Chemistry, Oncology East, Pfizer Global Research & Development

5:00 Close of Day


5:30-8:30 pm Recommended Dinner Short Course* 

SC14 Antibody Conjugate Therapeutics: Potential and Challenges

*Separate registration required.


Day 1 | Day 2 | Download Brochure